Golgi Protein 73: Charting New Territories in Diagnosing Significant Fibrosis in MASLD: a Prospective Cross-sectional Study

Overview

Journal Front Endocrinol (Lausanne)

Date 2025 Jan 28

PMID 39872312

Authors

Shan Hong

Ziyu Liu

Ping Li

Jing Zhang

Hongshan Wei

Affiliations

Soon will be listed here.

Abstract

Objectives: To explore the correlation between serum Golgi protein 73 (GP73) levels and the degree of fibrosis in Metabolic dysfunction associated steatotic liver disease (MASLD); to establish a non-invasive diagnostic algorithm based on serum GP73 and liver elasticity.

Methods: This is a prospective cross-sectional study, including 228 patients diagnosed with MASLD from May 2018 to January 2024 at two tertiary hospitals. Clinical data and hepatic pathological features and the correlation between serum GP73 and liver fibrosis were assessed. A new algorithm was conducted after logistic regression. Receiver Operating Characteristic (ROC) curve was used to compare its diagnostic performance with traditional models.

Results: Significant fibrosis was diagnosed in 37.2% (85/228) patients. Serum GP73 levels were markedly higher in patients with significant fibrosis than in those without (128 ng/mL v.s 46 ng/mL, p< 0.001). Serum GP73 levels independently predicted significant liver fibrosis (adjusted odds ratio, aOR 1.028, p< 0.001). A new algorithm based on GP73 was developed with a higher area under ROC (AUC) of 0.840 than that of Fibrosis index-4 (p< 0.001).

Conclusions: Serum GP73 is an independent risk factor for significant liver fibrosis in MASLD, and the GFA (GP73-Fibroscan-Age) model has good diagnostic efficacy for significant liver fibrosis.

Citing Articles

Diagnostic Accuracy of Golgi Protein 73 (GP73) for Liver Fibrosis Staging in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Scoping Review and Cohort Study.

Pecoraro V, Nascimbeni F, Cuccorese M, Gabrielli F, Fasano T, Trenti T Diagnostics (Basel). 2025; 15(5).

PMID: 40075792 PMC: 11898419. DOI: 10.3390/diagnostics15050544.

References

Zhou B . Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults--study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci. 2002; 15(1):83-96. View

Younossi Z, Golabi P, Paik J, Henry A, Van Dongen C, Henry L . The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77(4):1335-1347. PMC: 10026948. DOI: 10.1097/HEP.0000000000000004. View

Marrero J, Kulik L, Sirlin C, Zhu A, Finn R, Abecassis M . Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68(2):723-750. DOI: 10.1002/hep.29913. View

Xia Y, Zhang Y, Shen M, Xu H, Li Z, He N . Golgi protein 73 and its diagnostic value in liver diseases. Cell Prolif. 2018; 52(2):e12538. PMC: 6496820. DOI: 10.1111/cpr.12538. View

Graupera I, Thiele M, Serra-Burriel M, Caballeria L, Roulot D, Wong G . Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. Clin Gastroenterol Hepatol. 2021; 20(11):2567-2576.e6. DOI: 10.1016/j.cgh.2021.12.034. View

Bedossa P, Carrat F . Liver biopsy: the best, not the gold standard. J Hepatol. 2008; 50(1):1-3. DOI: 10.1016/j.jhep.2008.10.014. View

Wei H, Li B, Zhang R, Hao X, Huang Y, Qiao Y . Serum GP73, a marker for evaluating progression in patients with chronic HBV infections. PLoS One. 2013; 8(2):e53862. PMC: 3572132. DOI: 10.1371/journal.pone.0053862. View

Hemken P, Qin X, Sokoll L, Jackson L, Feng F, Li P . Validation of the novel GLAS algorithm as an aid in the detection of liver fibrosis and cirrhosis based on GP73, LG2m, age, and sex. Clin Proteomics. 2023; 20(1):53. PMC: 10683319. DOI: 10.1186/s12014-023-09444-7. View

Kladney R, Bulla G, Guo L, Mason A, Tollefson A, SIMON D . GP73, a novel Golgi-localized protein upregulated by viral infection. Gene. 2000; 249(1-2):53-65. PMC: 7127640. DOI: 10.1016/s0378-1119(00)00136-0. View

10.

Goldberg D, Ditah I, Saeian K, Lalehzari M, Aronsohn A, Gorospe E . Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology. 2017; 152(5):1090-1099.e1. PMC: 5367965. DOI: 10.1053/j.gastro.2017.01.003. View

11.

DeLong E, Delong D, Clarke-Pearson D . Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44(3):837-45. View

12.

Pan X, Wang L, Pan A . Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol. 2021; 9(6):373-392. DOI: 10.1016/S2213-8587(21)00045-0. View

13.

Liu X, Wan X, Li Z, Lin C, Zhan Y, Lu X . Golgi protein 73(GP73), a useful serum marker in liver diseases. Clin Chem Lab Med. 2011; 49(8):1311-1316. DOI: 10.1515/CCLM.2011.640. View

14.

Miura K, Hayashi H, Kamada Y, Fujii H, Takahashi H, Oeda S . Agile 3+ and Agile 4, noninvasive tests for liver fibrosis, are excellent formulae to predict liver-related events in nonalcoholic fatty liver disease. Hepatol Res. 2023; 53(10):978-988. DOI: 10.1111/hepr.13938. View

15.

Zhang X, Zhu C, Wang T, Jiang H, Ren Y, Zhang Q . GP73 represses host innate immune response to promote virus replication by facilitating MAVS and TRAF6 degradation. PLoS Pathog. 2017; 13(4):e1006321. PMC: 5398727. DOI: 10.1371/journal.ppat.1006321. View

16.

Gu Y, Chen W, Zhao Y, Chen L, Peng T . Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases. Ann Clin Biochem. 2008; 46(Pt 1):38-43. DOI: 10.1258/acb.2008.008088. View

17.

Huang X, Yu R, Tan X, Guo M, Xia Y, Zou H . Comparison of NAFLD, MAFLD, and MASLD Prevalence and Clinical Characteristics in Asia Adults. J Clin Exp Hepatol. 2024; 15(1):102420. PMC: 11570951. DOI: 10.1016/j.jceh.2024.102420. View

18.

Balkhed W, Aberg F, Nasr P, Ekstedt M, Kechagias S . Repeated measurements of non-invasive fibrosis tests to monitor the progression of non-alcoholic fatty liver disease: A long-term follow-up study. Liver Int. 2022; 42(7):1545-1556. PMC: 9314831. DOI: 10.1111/liv.15255. View

19.

Gatselis N, Tornai T, Shums Z, Zachou K, Saitis A, Gabeta S . Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients. World J Gastroenterol. 2020; 26(34):5130-5145. PMC: 7495033. DOI: 10.3748/wjg.v26.i34.5130. View

20.

Yang Y, Liu Q, Zhang H, Zhao H, Mao R, Li Z . Silencing of GP73 inhibits invasion and metastasis via suppression of epithelial-mesenchymal transition in hepatocellular carcinoma. Oncol Rep. 2017; 37(2):1182-1188. DOI: 10.3892/or.2017.5351. View